Assessment of Treatment Response With Faslodex (500 mg) in Standard Clinical Practice Through a Retrospective Study.

Trial Profile

Assessment of Treatment Response With Faslodex (500 mg) in Standard Clinical Practice Through a Retrospective Study.

Completed
Phase of Trial: Phase IV

Latest Information Update: 08 Jun 2016

At a glance

  • Drugs Fulvestrant (Primary)
  • Indications Advanced breast cancer
  • Focus Therapeutic Use
  • Acronyms EFFICACY
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 25 Apr 2016 Status changed from recruiting to completed.
    • 20 Aug 2013 Planned end date changed from 1 Aug 2012 to 1 Mar 2014 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top